## TECH: Bio-Techne Corp - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.83 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-7.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($58.71)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Mackenzie Financial Corp Raises Stock Holdings in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251201T121908 | Somewhat-Bullish | Relevance: 99%
- Mackenzie Financial Corp increased its stake in Bio-Techne Corp (NASDAQ:TECH) by 2.9% to 2,619,101 shares, valued at approximately $134.8 million. This comes amidst a "Moderate Buy" average analyst rating and updated price targets from several firms. Bio-Techne reported Q3 EPS of $0.42, meeting estimates, and revenue of $286.6 million, slightly below expectations.

**2. Edgestream Partners L.P. Has $11.81 Million Holdings in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251202T105226 | Bullish | Relevance: 98%
- Edgestream Partners L.P. increased its stake in Bio-Techne Corp (NASDAQ:TECH) by 15.9% in Q2, now holding 229,625 shares valued at $11.81 million. Institutional investors own approximately 98.95% of the company, and analysts have a "Moderate Buy" rating with a consensus price target of $70.92. Bio-Techne reported $0.42 EPS in line with estimates and declared a quarterly dividend of $0.08 per share.

**3. Capital Fund Management S.A. Invests $4.89 Million in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251202T100713 | Somewhat-Bullish | Relevance: 98%
- Capital Fund Management S.A. recently acquired a new stake of 95,046 shares in Bio-Techne Corp (NASDAQ:TECH) valued at approximately $4.89 million during the second quarter. This investment makes Capital Fund Management S.A. a significant institutional holder, owning about 0.06% of Bio-Techne. The article also details other institutional investor activities, analyst ratings, and Bio-Techne's recent financial performance and dividend announcement.

**4. Grandeur Peak Global Advisors LLC Has $7.13 Million Stock Position in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251201T094924 | Somewhat-Bullish | Relevance: 98%
- Grandeur Peak Global Advisors LLC significantly increased its stake in Bio-Techne Corp ($TECH) by 186.3% in Q2, bringing their total holdings to 138,514 shares valued at $7.13 million. Institutional investors now own 98.95% of the company, which has a market cap of $10.03 billion and a P/E ratio of 139.88. Analysts have a consensus "Moderate Buy" rating with an average price target of $70.92 for Bio-Techne, which recently reported Q2 earnings of $0.42 per share and revenue of $286.6 million.

**5. Bio-Techne Corp $TECH Shares Bought by JPMorgan Chase & Co.**
- Source: MarketBeat | 20251201T102333 | Neutral | Relevance: 98%
- JPMorgan Chase & Co. significantly increased its stake in Bio-Techne Corp (NASDAQ:TECH) by 52.9% in Q2, acquiring 470,339 additional shares to own a total of 1,358,823 shares valued at approximately $69.9 million. This move comes as Bio-Techne reported Q2 EPS of $0.42, meeting estimates, but revenue of $286.56 million fell below consensus and was down 1% year-over-year. The company has a "Moderate Buy" consensus analyst rating with an average target price of $70.92, despite a high P/E ratio of 139.88.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Argus Research | $68 | $65 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Argus Research | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 28.7x stretched relative to 11% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.5B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 28.7 |
| Current P/E | 31.8 |
| YoY Growth | 10.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 9.6% to 1.9% (-7.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.1pp (needs >4.0% for momentum thesis). MRS_5 (-2.8%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.7% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 55.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.88% (CS: 77) | Neutral |
| RSI_14 | 55.4 | Neutral |
| MACD Histogram | 0.39 | Bullish |
| vs SMA20 | 1.036x | Above |
| vs SMA50 | 1.045x | Above |
| vs SMA200 | 1.134x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $62.95
- **Stop Loss:** $58.71 (6.7% risk)
- **Target:** $71.43 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 235
- **Position Value:** $14,793.25
- **Portfolio %:** 14.79%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*